Originally published as JCO Early Release 10.1200/JCO.2004.08.080 on October 4 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bezjak, A. Articles by Eisenhauer, E. Search for Related Content PubMed PubMed Citation Articles by Bezjak, A. Articles by Eisenhauer, E. Social Bookmarking                            What's this?

Quality of Life in Ovarian Cancer Patients: Comparison of Paclitaxel Plus Cisplatin, With Cyclophosphamide Plus Cisplatin in a Randomized Study

From the University Health Network, Princess Margaret Hospital, Toronto; National Cancer Institute of Canada Clinical Trials Group, Queen's University Cancer Research Institute, Kingston, Ontario; QOL Consulting, Vancouver, British Columbia; Tom Baker Cancer Centre, Calgary, Alberta, Canada; Chinese University of Hong Kong, Hong Kong, China; and Institut Jules Bordet, Brussels, Belgium

Address reprint requests to Andrea Bezjak, MD, Princess Margaret Hospital/University Health Network, 610 University Avenue, Suite 5-911, Toronto, ON M5G 2M9, Canada; e-mail: andrea.bezjak{at}rmp.uhn.on.ca

PURPOSE: Formal quality-of-life (QOL) assessments may contribute important information on patient symptoms. Despite many trials of systemic chemotherapy in ovarian cancer, reports of its effect on QOL are few.

PATIENTS AND METHODS: QOL was assessed in an Intergroup randomized trial comparing paclitaxel plus cisplatin to cyclophosphamide plus cisplatin in women with advanced ovarian cancer. One hundred fifty-two eligible patients accrued in Canada completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 and a trial-specific checklist at baseline (after surgical debulking) and at regular intervals during and after chemotherapy. Mean change scores over time in the two arms were calculated.

RESULTS: Compliance with QOL questionnaire completion was excellent (81% to 93%). In general, deterioration was seen in the QOL domains immediately after chemotherapy (day 8 of cycle 1), followed by clinically meaningful improvements compared with baseline (change scores 10) in both arms during the treatment period in a number of domains and items, including global QOL, emotional function, social function, fatigue, pain, sleep, constipation, appetite, abdominal swelling, and abdominal cramps. Improvements in global QOL persisted for the duration of follow-up. More neurosensory effects and myalgia were documented in the paclitaxel arm; however, this did not adversely affect global or other domains of QOL and improved once chemotherapy was completed.

CONCLUSION: Improvement from baseline in QOL measures was seen in both treatment arms. The greater neurologic and muscle toxicity of paclitaxel did not adversely influence QOL. QOL data can contribute useful information on the experience of symptoms and their time course, which may assist patients and physicians in their discussion about the anticipated effects of therapy.

Supported by a core grant from the National Cancer Institute of Canada, and in part by funding from Bristol Myers-Squibb and the EORTC Data Centre.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. R. Greimel, V. Bjelic-Radisic, J. Pfisterer, F. Hilpert, F. Daghofer, and A. du Bois Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel J. Clin. Oncol., February 1, 2006; 24(4): 579 - 586. [Abstract] [Full Text] [PDF]